10921/13381US=2 / Mama
Sweep FCGJ, Thomas CMG, Schmitt M. General topics: analytical aspects of biomarker immunoassays in cancer research. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 17-30. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

CANCER DE MAMA; BIOMARCADORES; IMUNOENSAIOS; MARCADORES TUMORAIS


10922/13381US=2 / Mama
Kim C, Paik S. General topics: tissue microarrays: state of the art, pitfalls, and promises. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 31-44. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

CANCER DE MAMA; BIOMARCADORES; TISSUE MICROARRAYS; ENSAIOS CLINICOS MULTICENTRICOS; TISSUE ARRAY


10923/13381US=2 / Mama
De Bortoli M, Biglia N. Assays for gene expression and post-translational protein abnormalities: gene expression profiling with DNA microarrays: revolutionary tools to help diagnosis, prognosis, treatment guidance, and drug discovery. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 47-61. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

CANCER DE MAMA; ENSAIOS DA EXPRESSAO DO GENE; ANORMALIDADES POS-TRADUCIONAIS; PERFIL DE EXPRESSAO GENICA; MICROARRANJOS DE DNA


10924/13381US=2 / Mama
Kim C, Song Y, Paik S. Assays for DNA abnormalities: assays for gene amplification. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 65-77. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

CANCER DE MAMA; ANOMALIAS DO DNA; ENSAIOS PARA AMPLIFICACAO DO GENE; TRASTUZUMABE; TESTE HER-2


10925/13381US=2 / Mama
Daidone MG, Silvestrini R, Amadori D. Tissue predictive biomakers: cell kinetics. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 81-109. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES DE TECIDO PREDITIVOS; CINETICA CELULAR; PADRONIZACAO DO ENSAIO; ENSAIOS CLINICOS; VARIACOES POS-TRATAMENTO


10926/13381US=2 / Mama
Duffy MJ. Tissue predictive biomakers: urokinase-type plasminogen activator and PAI-1. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 111-28. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; UROQUINASE; PLASMINOGENIO; PAI-1; CANCER; MARCADORES TUMORAIS; CANCER DE MAMA


10927/13381US=2 / Mama
Duffy MJ. Tissue predictive biomakers: predictive value of c-erb-B2 for endocrine therapy and chemotherapy in breast cancer. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 129-57. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; VALOR PREDITIVO DE C-ERB-B2; HORMONIOTERAPIA; QUIMIOTERAPIA; CANCER DE MAMA; TRASTUZUMABE


10928/13381US=2 / Mama
Mass R. Tissue predictive biomakers: erb-B2 as a therapeutic target. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 159-75. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; ERB-B2; ALVO TERAPEUTICO; CANCER DE MAMA; HER2; TRASTUZUMABE; ANTICORPOS MONOCLONAIS


10929/13381US=2 / Mama
Ciardiello F, Troiani T, Tortora G. Tissue predictive biomakers: the epidermal growth factor receptor pathway as a selective molecular-targeted treatment in human breast cancer. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 177-91. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCAORES PREDITIVOS; FATOR DE CRESCIMENTO EPIDERMICO; VIA RECEPTOR; CANCER DE MAMA; EGF; EGFR


10930/13381US=2 / Mama
Kandioler D, Jakesk R. Tissue predictive biomakers: p53 as a prognostic and predicitive indicator. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 193-209. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; P53; INDICADOR DE PROGNOSTICO


10931/13381US=2 / Mama
Braun S, Seeber J, Marth C. Predictive biomarkers in body fluids: occult metastatic cells in breast cancer patients. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 213-33. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; FLUIDOS CORPORAIS; CELULAS METASTATICAS; CANCER DE MAMA; PROGNOSTICO


10932/13381US=2 / Mama
Lipton A, Demmers L, Leitzel K, Ali SM, Neumann R, Price CP, Carney WP. Predictive biomarkers in body fluids: circulating HER2/neu: clinical utility. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 235-65. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; FLUIDOS CORPORAIS; CIRCULACAO HER2/NEU; ONCOPROTEINA; CANCER DE MAMA


10933/13381US=2 / Mama
Sarmiento R, Franceschini R, Meo S, Gion M, Longo R, Gaspirini G. Predictive biomarkers in body fluids: circulating vascular endothelial growth factor. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 267-92. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; FLUIDOS CORPORAIS; CIRCULACAO; FATOR DE CRESCIMENTO ENDOTELIAL VASCULAR; CANCER DE MAMA; ANGIOGENESE; TERAPIA; PROGNOSTICO


10934/13381US=2 / Mama
Hawes D, Cote RJ. Predictive biomarkers in body fluids: detection of early tumor dissemination in patients with breast cancer. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 293-321. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES PREDITIVOS; FLUIDOS CORPORAIS; DETECCAO DE DISSEMINACAO DO TUMOR PRECOCE; CANCER DE MAMA; MEDULA OSSEA; CELULAS TUMORAIS CIRCULANTES; DISSEMINACAO DO TUMOR NO INICIO; CITOMETRIA DE FLUXO; IMUNO-HISTOQUIMICA; SEPARACAO IMUNO-MAGNETICA; LINFONODOS; MICROMETASTASES; METASTASES OCULTAS; SANGUE PERIFERICO; REACAO REVERSA DA CADEIA DE TRANSCRIPTASE-POLIMERASE; LINFONODO SENTINELA


10935/13381US=2 / Mama
Hawes D, Cote RJ. Future directions: new technologies/new markers/new challenges. In: Gasparini G, Hayes DF. Biomarkers in breast cancer: molecular diagnostics for predicting and monitoring therapeutic effect. New Jersey: Humana Press, 2006. p. 325-31. (Cancer Drug Discovery and Development) ISBN 978-1-58829-227-4.

BIOMARCADORES; NOVAS TECNOLOGIAS; DESENVOLVIMENTO


10936/13381US=20 / Biol/Mol
Smiley S, Wong MKK, Mousa SA. Methods for monitoring of the anti-angiogenic activity of agents in patients: novel trial design. In: Staton CA, Lewis C, Bicknell R. Angiogenesis assays: a critical appraisal of current techniques. New Jersey: John Wiley & Sons, 2006. p. 341-59. ISBN 978-0-470-01600-8.

METODOS DE MONITORAMENTO DA ATIVIDADE ANTI-ANGIOGENICA; ANGIOGENESE; ENSAIOS CLINICOS; CANCER; DISTURBIOS VASCULARES; IMAGEM; BIOMARCADORES; TERAPIA ADJUNTA


10937/13381US=2 / Biol/Mol
Gülow K, Kaminski M, Krammer PH. Death receptor: the role of CD95/CD95 ligand signaling in apoptosis and cancer. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 3-30. ISBN 978-3-527-31237-5.

RECEPTOR MORTE; SISTEMA CD95; SISTEMA CD95L; SINALIZACAO DA APOPTOSE; CANCER; MAQUINARIA APOPTOTICA; VIA INTRINSECA; VIA EXTRINSECA; MITOCONDRIAS; MECANISMOS DE RESISTENCIA; ANGIOGENESE


10938/13381US=2 / Biol/Mol
Walczak H, Koschny R, Willen D, Schader MB, Sykora J, Ganten TM, Haas TL. Death receptor: the TRAIL receptor-ligand system: biochemistry of apoptosis induction, therapeutic potential for cancer treatment and physiological function. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 31-92. ISBN 978-3-527-31237-5.

RECEPTOR MORTE; SISTEMA DE RECEPTOR-LIGANTE TRAIL; BIOQUIMICA DA INDUCAO DE APOPTOSE; POTENCIAL TERAPEUTICO; CANCER. TERAPIA; FUNCAO FISIOLOGICA; ATIVACAO DA CASPASE; FAMILIA BCL-2; UBIQUITINA; TERAPIA GENETICA; INFECCAO VIRAL; IMUNOPATOLOGIAS; DOENCAS AUTO-IMUNES; TRANSPLANTE ALOGENICO DE CELULAS-TRONCO HEMATOPOETICAS


10939/13381US=2 / Biol/Mol
Wajant H. Death receptor: mechanisms of tumor necrosis factor-induced cell death. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 93-119. ISBN 978-3-527-31237-5.

RECEPTOR DE MORTE; MORTE CELULAR; FATOR DE NECROSE TUMORAL; APOPTOSE; CANCER. TERAPIA


10940/13381US=2 / Biol/Mol
Micheau O. Death receptor: cellular FLICE-inhibitory protein: an update. In: Debatin K-M, Fulda S. Apoptosis and cancer therapy: from cutting-edge science to novel therapeutic concepts. Weinheim: Wiley-VCH, 2006. p. 120-56. ISBN 978-3-527-31237-5.

CANCER; RECEPTOR MORTE; PROTEINA INIBITORIA DA FLICE; GENE FLIP


Primeira | Anterior | Próxima | Última